Bladder cancer: can we move beyond chemotherapy?
Since the advent of cisplatin-based chemotherapy, cytotoxic combination chemotherapy remains the mainstay of treatment for locally advanced and metastatic urothelial malignancies. The current paradigm of combining novel agents with cytotoxic chemotherapy without any understanding of the underlying biology of urothelial cancer has limited the impact of developing novel agents for this disease. Current research investigating the biology of bladder cancer, including the role of p53, EMT, EGFR-related pathways, and anti-angiogenic pathways, may potentially impact the future development of novel agents targeting urothelial malignancies. Additionally, the use of novel gene therapy to mediate enhanced interferon expression in the bladder using adenoviral vectors, and enhancing tumor recognition strategies using the immune system with vaccines and anti-CTLA4 antibodies, are of interest. It is hoped that through these efforts we may soon move beyond the traditional cytotoxic chemotherapy paradigm, developing combinations that are more active and less toxic for all patients with urothelial cancer.
Siefker-Radtke
Arlene
A
Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1155 Pressler Street, Houston, TX 77030, USA. asiefker@mdanderson.org
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D000093542:Gemcitabine
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003841:Deoxycytidine; D000068258:Bevacizumab; D002945:Cisplatin; D000093542:Gemcitabine
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72
17360461
J Urol. 1985 Mar;133(3):403-7
4038749
Cancer Res. 1997 Dec 1;57(23):5281-5
9393750
Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):389-94
17692556
Clin Cancer Res. 2003 Jul;9(7):2583-6
12855634
J Clin Oncol. 2001 Oct 15;19(20):4005-13
11600601
J Clin Oncol. 2004 Jan 15;22(2):220-8
14665607
J Clin Oncol. 2009 Sep 1;27(25):4062-7
19636012
J Clin Oncol. 2000 Sep;18(17):3068-77
11001674
Clin Cancer Res. 2008 Mar 1;14(5):1478-86
18316572
J Clin Oncol. 1994 Mar;12(3):483-8
7509853
J Clin Oncol. 1995 Sep;13(9):2272-7
7666085
J Urol. 2001 Oct;166(4):1275-9
11547057
J Immunother. 2008 Nov-Dec;31(9):849-57
18833002
Clin Cancer Res. 1995 Oct;1(10):1189-94
9815911
J Urol. 2004 Feb;171(2 Pt 1):570-4
14713761
J Natl Cancer Inst. 2008 Oct 1;100(19):1401-11
18812553
Clin Cancer Res. 2006 Aug 1;12(15):4671-7
16899617
J Clin Oncol. 1993 Mar;11(3):408-14
7680373
Cancer Immun. 2003 Dec 18;3:19
14680360
Clin Cancer Res. 2009 Aug 15;15(16):5060-72
19671845
Clin Cancer Res. 2001 Aug;7(8):2440-7
11489824
J Natl Cancer Inst. 1995 Nov 1;87(21):1603-12
7563203
J Urol. 2009 Sep;182(3):907-13
19616250
Eur J Surg Oncol. 2006 May;32(4):439-44
16517112
Cancer. 2000 Apr 1;88(7):1671-8
10738226
Anticancer Res. 1994 May-Jun;14(3B):1317-24
7915094
Mol Ther. 2004 Sep;10(3):525-32
15336652
J Clin Oncol. 2009 Jun 1;27(16):2592-7
19414678
Stat Med. 2000 Apr 30;19(8):1011-28
10790677
Am J Clin Pathol. 1994 Feb;101(2):166-76
7906919
J Clin Oncol. 2001 May 15;19(10):2638-46
11352955
Urol Oncol. 2004 Jan-Feb;22(1):1-6
14969795
J Clin Oncol. 1990 Jun;8(6):1050-5
2189954
J Clin Oncol. 2002 Mar 1;20(5):1361-7
11870180
N Engl J Med. 2003 Aug 28;349(9):859-66
12944571
J Natl Cancer Inst. 2002 Sep 4;94(17):1320-9
12208897
J Urol. 2003 Apr;169(4):1295-8
12629346